Accredited clinical laboratory and life sciences company

2015

November 20 - UPCOMING PRESENTATION at the 3rd National Congress on Colorectal Cancer (Prague, CZ)

On December 11, Genomac CEO Dr. Marek Minarik will be one of the main speakers during the 3rd National Congress on Colorectal Cancer (3NCCC) opening session with a presentation titled "Molecular biology of colorectal cancer". The congress is a bi-annual meeting organized by the Czech Society for Gastrointestinal Oncology in association with the European Society of Digestive Oncology (ESDO). The foundation of the meeting go back to 2011 when the first congress was endorsed by the Czech president Vaclav Havel (photo gallery).

SGO ESDO logo

August 24 - UPCOMING PRESENTATION at ITP 2015 Conference (Helsinki, Finland)

On September 1 Genomac CEO Dr. Marek Minarik will present a lecture during the 22nd International Symposium on Electro- and Liquid Phase-Separation Techniques (ITP2015) and the 8th Nordic Separation Science (NoSSS) symposium in Helsinki, Finland. The lecture "Denaturing Capillary Electrophoresis (DCE): Resurrection of an old times DNA mutation detection technique into the new times cancer monitoring tool" will be presented during ITP session 6.

 

ASCO2015

May 28 - UPCOMING PRESENTATION at ASCO 2015 Annual Meeting (American Society of Clinical Oncology, Chicago, USA)

A poster  co-authored by Genomac research team will be presented during the ASCO 2015 meeting (May 29 - June 2, 2015, Chicago, IL).

The poster no. 3594 titled "Monitoring Minimal Residual Disease (MRD) by KRAS Mutation Burden in Urinary or Plasma Circulating Tumor (ct) DNA in Colorectal Cancer (CRC) Patients with Resectable Liver Metastases" will be presented during Gastrointestinal (Colorectal) Cancer session on Monday June 1, 2015, 8:00 – 11:30 a.m. EDT. The presentation results from an ongoing collaboration with Trovagene, Inc. on the implementation of Precision Cancer MonitoringSM (PCM) technology utilizing urine of cancer patients as source material for genomic analysis. A longitudinal data comparing levels of circulating-tumor DNA in patients plasma and urine will be shown, demonstrating clinical utility of the urine-based approach to the metastatic disease treatment monitoring.

 

 

web en OPPK

web en PRAHAEU           

 

 

Completion of EU supported project

Between February 1, 2014 and February 28, 2015 Genomac International, s.r.o. has conducted an investment project titled „Systems for complex analysis of genetic data" (CZ.2.16/3.300/22558), with support from European regional development fund – within the Operational Program Prague - Competitiveness (OPPK).

Modern instrumental equipment for DNA analysis, including an analyzer for sensitive detection of DNA mutations has been acquired allowing significant improvement in competitiveness of the company, which is focused on genetic testing and use of DNA analyses in research and development as well as genetic identity, forensic genetic identification, recreational genetics and biobanking.

EUROPEAN REGIONAL DEVELOPMENT FUND
PRAHA & EU: WE INVEST IN YOUR FUTURE

 

AACR2015

March 4 - UPCOMING PRESENTATION at AACR 2015 (American Association of Cancer Research, Philadelphia, USA)

Two posters authored by Genomac will be presented during the 106th Annual Meeting of the American Association for Cancer Research (April 18 - 22, 2015, Philadelphia, PA).

A validation of sensitive and cost-effective liquid-biopsy technique will be demonstrated on extended data including a total of 299 patients with colorectal, lung and pancreatic tumors. A poster No. 2406 titled "Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers" will be presented during the Clinical Research, Circulating Free DNA 1 session, Poster Section 21 on Monday April 20, 2015. The work is a result of collaborative study bringing together 12 clinical groups from major Complex oncology centers in Czech Republic.

Also during AAR 2015 a poster co-authored by Genomac titled "Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases" will be presented during the Clinical Research, Circulating Free DNA 22 session, Poster Section 21 on Wednesday April 22, 2015. The presentation is a joint research conducted with researchers from Trovagene, Inc. directed at ultra-sensitive detectiopn of ctDNA in plasma and urine of colorectal cancer patients.

 

January 16 - GENOMAC SET TO PRESENT AT MAJOR DOMESTIC ONCOLOGY CONFERENCE

pragueONCODr. Lucie Benesova, Genomac's Chief Scientific Director is set to give a lecture at the annual PragueONCO conference - a major oncology event in the Czech Republic. The presentation titled "New opportunities for non-invasive monitoring of cancer patients: detection of circulating tumor DNA in plasma and urine" will be presented during the "Direction of oncology in the 21st century" section on Thursday, January 21. The presentation will highlight the current boom in the development and application of liquid biopsy technology. It will also include Genomac's recent advances in the methodology of detecting and monitoring circulating tumor DNA in plasma. A new approach of ctDNA detection in urine of cancer patients and associated clinical data from ongoing collaboration with Trovagene, Inc. - will be presented for the first time to domestic audience.

 

 

ASCOGI2015
January 8 - UPCOMING PRESENTATION at ASCO GI (Gastrointestinal cancers symposium, San Francisco, USA)

Two posters authored by Genomac will be presented during the 2015 Gastrointestinal Cancers Symposium (January 15-17, 2015, in San Francisco, California).

A poster titled “Evaluation of circulating-tumor DNA (ctDNA) as a source material for molecular phenotyping of colorectal tumors.” (Abstract 642, BOARD C34) will be presented in the "General Poster Session C and Trials in Progress Session C: Cancers Of The Colon, Rectum, And Anus". It is a result of a collaboration between researchers from Genomac and clinicians at the Department of Internal Medicine, First Faculty of Medicine and the Military University Hospital Prague and the 2nd Department of Internal Medicine, University Hospital Hradec Kralove. The presented data relates to evaluating molecular phenotypic profiles for prediction of a long-term outcome of colorectal cancer patients using a nover approach termed "liquid biopsy" a field expored extensively by Genomac researchers.

A poster titled "Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations." (Abstract 654, BOARD C46) will also be presented in the "General Poster Session C and Trials in Progress Session C: Cancers Of The Colon, Rectum, And Anus". Resulting from a collaboration between Genomac and Trovagene, Ins. a new exciting data will be presented using a novel approach for detection of actionable oncogenic mutations in plasma and urine of colorectal cancer patients.